Earnings Estimates Moving Higher for Spark Therapeutics (ONCE): Time to Buy? – Tale of the Tape

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ONCE’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Spark Therapeutics could be a solid choice for investors.

Current Quarter Estimates for ONCE

In the past 30 days, estimates have narrowed from a loss of 93 cents a share, to a loss of 61 cents today, a move of 34.4%.

Current Year Estimates for ONCE

Meanwhile, Spark Therapeutics’ current year figures are also looking quite promising, with estimates narrowing from a loss of $1.90 per share 30 days ago to a loss of $1.34 per share today, a move of 29.5%.

Bottom Line

The stock has also started to move higher lately, adding 16.1% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>